Form 4 for SMMT Summit Therapeutics Inc.

Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-30 · accession 0001599298-25-000107 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2025-06-02	2025-05-30	SMMT	Zanganeh Mahkam	Co-CEO, Dir, 10%	M - OptEx	$2.64	+74.5K	555.75M	+0.0%	+$196.8K
DI	2025-06-02	2025-05-30	SMMT	Zanganeh Mahkam	Co-CEO, Dir, 10%	M - OptEx	$0.00	-74.5K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-05-30	M	A	74,545	$2.64	555,754,696	I By Spouse	—	—	(F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
2	Derivative	Stock Option (right to buy)	2025-05-30	M	D	74,545	$0.00	0	I By Spouse	$2.64 · — to 2034-01-02	74,545 Common Stock	(F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. (F3) The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024.